Search our Database of Scientific Publications and Authors

I’m looking for a
    Update of the human parvovirus B19 biology.
    Transfus Clin Biol 2016 Feb 6;23(1):5-12. Epub 2016 Jan 6.
    Pôle biologie-pathologie-physiologie, CHU Saint-Louis, AP-HP, 75010 Paris, France. Electronic address:
    Since its discovery, the human parvovirus B19 (B19V) has been associated with many clinical situations in addition to the prototype clinical manifestations, i.e. erythema infectiosum and erythroblastopenia crisis. The clinical significance of the viral B19V DNA persistence in sera after acute infection remains largely unknown. Such data may constitute a new clinical entity and is discussed in this manuscript. In 2002, despite the genetic diversity among B19V viruses has been reported to be very low, the description of markedly distinct sequences showed a new organization into three genotypes. The most recent common ancestor for B19V genotypes was estimated at early 1800s. B19V replication is enhanced by hypoxia and this might to explain the high viral load detected by quantitative PCR in the sera of infected patients. The minimum infectious dose necessary to transmit B19V infection by the transfusion of labile blood products remains unclear. At the opposite, the US Food and Drug Administration proposed a limit of 10(4)IU/mL of viral DNA in plasma pools used for the production of plasma derivatives. Recently, a new human parvovirus (PARV4) has been discovered. The consequences on blood transfusion of this blood-borne agent and its pathogenicity are still unknown.

    Similar Publications

    [Genetic diversity of human erythroviruses. Consequences on infectious safety of plasma derivatives].
    Transfus Clin Biol 2009 Nov-Dec;16(5-6):482-8. Epub 2009 Oct 31.
    Département des agents transmissibles par le sang, Institut national de la transfusion sanguine, 6, rue Alexandre-Cabanel, 75015 Paris, France.
    The B19 Parvovirus (B19V) has for a long time been considered as the unique human virus belonging to the genus Erythrovirus. The genetic diversity of B19V isolates has been shown to be very low. The isolation of a variant (V9 strain), with a sequence markedly distinct from that of B19V which led to attributing this classification to this family of viruses. Read More
    Advances in human B19 erythrovirus biology.
    J Virol 2010 Oct 14;84(19):9658-65. Epub 2010 Jul 14.
    Département des Agents Transmissibles par le Sang, Institut National de la Transfusion Sanguine, Paris, France.
    Since its discovery, human parvovirus B19 (B19V), now termed erythrovirus, has been associated with many clinical situations (neurological and myocardium infections, persistent B19V DNAemia) in addition to the prototype clinical manifestations, i.e., erythema infectiosum and erythroblastopenia crisis. Read More
    Existence of various human parvovirus B19 genotypes in Chinese plasma pools: genotype 1, genotype 3, putative intergenotypic recombinant variants and new genotypes.
    Virol J 2016 Sep 17;13(1):155. Epub 2016 Sep 17.
    Laboratory for Viral Safety of National Centre of Biomedical Analysis, Beijing Institute of Transfusion Medicine, No. 27 Taiping road, Haidian District, Beijing, 100850, China.
    Background: Human parvovirus B19 (B19V) is a frequent contaminant of blood and plasma-derived medicinal products. Three distinct genotypes of B19V have been identified. The distribution of the three B19V genotypes has been investigated in various regions or countries. Read More
    Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus.
    J Infect Dis 2007 May 21;195(9):1345-52. Epub 2007 Mar 21.
    Centre for Infectious Diseases, Western General Hospital, University of Edinburgh, Edinburgh, EH9 1QH, United Kingdom.
    Background: PARV4 and human bocavirus (HBoV) are newly discovered human parvoviruses with poorly understood epidemiologies and disease associations. We investigated the frequencies of persistence, tissue distribution, and influence of immunosuppression on replication of these viruses.

    Methods: At autopsy, bone marrow, lymphoid tissue, and brain tissue from human immunodeficiency virus (HIV)-infected individuals with acquired immunodeficiency syndrome (AIDS) and those without AIDS and from HIV-uninfected individuals were screened for parvovirus B19, PARV4, and HBoV DNA by means of quantitative polymerase chain reaction analyses. Read More